Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Guangzhou Saliai Stem Cell Science and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Human umbilical cord mesenchymal stem cells (UC-MSCs) developed by Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. are an investigational cell therapy for the treatment of ocular corneal burns, particularly chemical burns. These cells possess unique biological properties, including self-renewal, multidirectional differentiation, and potent immunomodulatory effects. In the context of corneal injury, UC-MSCs aim to accelerate tissue repair, reduce persistent inflammation, and inhibit pathological neovascularization (angiogenesis), which are common complications leading to vision loss. The therapy is administered via subconjunctival injection and has been evaluated in Phase 1/2 clinical trials (NCT03237442) to assess its safety and efficacy in humans following promising results in rabbit models of alkali-induced corneal injury.
- Other names
- UC-MSCshuman UC-MSCshuman umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.).